Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
- Sponsor
- Centre Francois Baclesse
- Study ID
- NCT04205799
- Phase
- PHASE2
- Status
- Completed
Conditions
- Advanced/Metastatic Cervical Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cabozantinib — DRUGCabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
Study Details
Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.
Key Dates
- Start date
- Jan 15, 2020
- Status verified
- Jun 2026
- Primary completion
- Jan 15, 2023
- Completion
- Jan 15, 2023
Study Design
- Enrollment
- 57 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CABOZANTINIBCabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
Primary Outcome Measure
Efficacy of Cabozantinib: Proportion of Patients With Disease Control Rate [ Time Frame: 3 months after cabozantinib treatment initiation. ]